EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers

David B Meya iD, Elizabeth Nalintya, Caleb P Skipper, Paul Kirumira, Peruth Ayebare, Rose Naluyima, Teopista Namuli, Fred Turya, Stewart Walukaga, Nicole Engen iD, Kathy H Hullsiek, Abduljewad Wele und 3 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae266 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von David B Meya und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Amphotericin B, Antifungal Agents, Antigens, Fungal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cryptococcal meningitis is a leading cause of AIDS-related mortality. Cryptococcal antigen (CrAg) predicts the development of meningitis. Historically, despite standard- of-care fluconazole, 25%–30% of asymptomatic CrAg-positive persons develop breakthrough meningitis or death. We evaluated whether adding single high-dose liposomal amphotericin B to standard pre-emptive fluconazole therapy could improve meningitis-free survival.

Methods

Participants with human immunodeficiency virus (HIV) and asymptomatic cryptococcal antigenemia in Uganda were randomized to liposomal amphotericin B (10 mg/kg once) with fluconazole or fluconazole alone through 24 weeks. We compared 24-week, meningitis-free survival time between treatment groups. After the second interim review, the Data Safety and Monitoring Board recommended no further enrollment of participants with low plasma CrAg lateral flow assay titers (≤1:80) due to futility. Herein, we present the results of participants with low plasma CrAg titers.

Results

168 participants enrolled into the ACACIA trial had low plasma CrAg titers (≤1:80). During 24 weeks of follow-up, meningitis or death occurred in 14.5% (12/83) of participants randomized to liposomal amphotericin B with fluconazole versus 10.6% (9/85) assigned to fluconazole alone (hazard ratio, 1.42; 95% CI, .60–3.36; P = .431). Adverse events were more frequent in participants assigned to the intervention versus standard-of-care (28% vs 12%; P = .011).

Conclusions

Among CrAg-positive persons with low titers (≤1:80), the addition of single-dose liposomal amphotericin B to fluconazole as pre-emptive therapy provided no additional clinical benefit. This trial provides supportive evidence that, in asymptomatic populations with low plasma CrAg titers, lumbar punctures are likely unnecessary as administration of meningitis treatment did not improve outcomes. Clinical Trials Registration Clinicaltrials.gov (NCT03945448).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningitis, CryptococcalAmphotericin BAntifungal AgentsAntigens, FungalHIV InfectionsAIDS-Related Opportunistic InfectionsHumansMaleFemaleAdultFluconazoleUgandaYoung Adult

Stichwörter der Autor:innen

HIVcryptococcal antigencryptococcosismeningitis

Substanzen

Amphotericin BAntifungal Agentsliposomal amphotericin BAntigens, FungalFluconazole

Autor:innen und Institutionen

  • Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: David B Meya, Nicole Engen, Radha Rajasingham

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Neurologic Disorders
  • NIH HHS
  • FIC NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Meya, D. B., Nalintya, E., Skipper, C. P., Kirumira, P., Ayebare, P., Naluyima, R., Namuli, T., Turya, F., Walukaga, S., Engen, N., Hullsiek, K. H., Wele, A., Dai, B., Boulware, D. R., & Rajasingham, R. (2025). Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae266

Vancouver

Meya DB, Nalintya E, Skipper CP, Kirumira P, Ayebare P, Naluyima R, et al. Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae266

BibTeX
@article{Meya2025,
  author = {Meya, David B and Nalintya, Elizabeth and Skipper, Caleb P and Kirumira, Paul and Ayebare, Peruth and Naluyima, Rose and Namuli, Teopista and Turya, Fred and Walukaga, Stewart and Engen, Nicole and Hullsiek, Kathy H and Wele, Abduljewad and Dai, Biyue and Boulware, David R and Rajasingham, Radha},
  title = {Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae266}
}
Kostenlos starten →